Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Experimental therapy

S Charache1

  • 1Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Hematology/Oncology Clinics of North America
|December 1, 1996
PubMed
Summary
This summary is machine-generated.

Current sickle cell disease treatments like bone marrow transplant and hydroxyurea therapy are under evaluation. Further research into long-term complications and combination therapies is needed to improve patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

American journal of hematology·2000
Same author

Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.

Seminars in hematology·1997
Same author

Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea.

Blood·1997
Same author

Eye disease in sickling disorders.

Hematology/oncology clinics of North America·1996
Same author

Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Medicine·1996
Same author

Treatment of sickling disorders.

Current opinion in hematology·1996
Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026
Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026
See all related articles

Area of Science:

  • Hematology
  • Pediatric Medicine
  • Clinical Therapeutics

Background:

  • Sickle cell disease (SCD) is a group of inherited red blood cell disorders.
  • Current treatments aim to manage symptoms and prevent complications.
  • Long-term effects of existing therapies require further investigation.

Purpose of the Study:

  • To review current and emerging treatments for sickle cell disease.
  • To highlight the need for understanding long-term complications.
  • To explore strategies for improving patient outlook.

Main Methods:

  • Evaluation of bone marrow transplantation.
  • Assessment of hydroxyurea therapy in various sickling disorders.
  • Review of prophylactic transfusion protocols for stroke prevention.

Related Experiment Videos

Main Results:

  • Several treatment modalities are under active investigation for SCD.
  • Long-term complications associated with these treatments are not fully elucidated.
  • Ongoing efforts focus on inhibiting sickling by reducing intracellular hemoglobin concentration.

Conclusions:

  • Combination therapies with different mechanisms of action show promise.
  • Optimized treatment schedules may enhance the prognosis for patients with sickling disorders.
  • Continued research is crucial for advancing SCD management.